Advanced Filters
noise
Found 563 clinical trials
S Sandro Pignata, MD, PhD

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery. The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a …

18 years of age Female Phase 3
Y Yongpeng Wang

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with Advanced FIGO Stage III or IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or primary peritoneal cancer following front-line platinum-based chemotherapy with QL1101. Eligible …

18 - 70 years of age Female Phase 2
A Anne-Sophie Maryns

A Performance Study of (Opportunistic) Salpingectomy

The goal of this clinical trial is to test the quality of the performance of opportunistic salpingectomies in women scheduled for adnexectomy. The main questions it aims to answer are: How many salpingectomies are incomplete? Are there any factors related to incomplete resection? Could the investigators develop a instruction video …

18 years of age Female Phase N/A
M Michael Frumovitz

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

18 years of age Female Phase 2
M Mary Beth Bartolotta, RN

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

The primary purpose of this study is to determine the response rate of patients with recurrent platinum resistant ovarian cancer when treated with oral minoxidil. Secondary objectives include estimating the time to disease progression while on minoxidil and to describe the toxicities of minoxidil when used for patients with recurrent …

18 - 90 years of age Female Phase 2

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile. AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to evaluate the efficacy and safety of AK104 combined with chemotherapy as …

18 - 75 years of age Female Phase 2
L Larissa Meyer, M D

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy

18 years of age All Phase N/A

Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)

Ⅶ. Study procedures (summary) Written informed consent must be obtained before any study specific procedures are undertaken. Qualified participants were identified at the pre-anesthesia evaluation clinic or ward. The informed consents are obtained from the patient in the ward at night before the operation. 2. The process of the experiment …

20 - 80 years of age Female Phase 4
T Tracy Crane, PhD

Trial of Exercise and Lifestyle in Women With Ovarian Cancer

An anticipated 200 women with newly diagnosed ovarian cancer scheduled to receive chemotherapy (adjuvant chemotherapy after surgery or neoadjuvant chemotherapy before surgery) will be recruited from Smilow Cancer Hospital Network at Yale Cancer Center (YCC) and Sylvester Comprehensive Cancer Center (SCCC) at University of Miami. Participants will be randomized to …

18 years of age Female Phase N/A
A Ashley O'Neil

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in participants with recurrent or persistent ovarian, fallopian …

18 years of age Female Phase 1

Simplify language using AI